Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2)
Sponsor: Albireo, an Ipsen Company
This observational or N/A phase trial investigates Progressive Familial Intrahepatic Cholestasis and is currently completed. Albireo, an Ipsen Company leads this study, which shows 33 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
33 versions recorded-
May 4, 2026 — Present [daily]
Completed
Phase: PHASE3 → None
-
Mar 2026 — May 2026 [monthly]
Completed PHASE3
-
Feb 2026 — Mar 2026 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2026 — Feb 2026 [monthly]
Active Not Recruiting PHASE3
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE3
▶ Show 28 earlier versions
-
Oct 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Nov 2024 — Aug 2025 [monthly]
Active Not Recruiting PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting PHASE3
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE3
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE3
-
Aug 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2022 — Aug 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2022 — Nov 2022 [monthly]
Recruiting PHASE3
-
Sep 2021 — Jun 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE3
-
Nov 2019 — Jan 2020 [monthly]
Recruiting PHASE3
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE3
-
Apr 2019 — Sep 2019 [monthly]
Recruiting PHASE3
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE3
Status: Enrolling By Invitation → Recruiting
-
Jan 2019 — Mar 2019 [monthly]
Enrolling By Invitation PHASE3
-
Nov 2018 — Jan 2019 [monthly]
Enrolling By Invitation PHASE3
Status: Not Yet Recruiting → Enrolling By Invitation
-
Oct 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Sep 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
Open Label Extension Study to evaluate long term safety and persistence of effect of A4250 in children with PFIC.
Contact Information
- Albireo, an Ipsen Company
For direct contact, visit the study record on ClinicalTrials.gov .